Bulk drug imports from China slow

There is still some way until India’s dependence on imports of active pharmaceutical ingredients (APIs) and intermediates from China reduces, but the growth rate of imports has come down.
While the production-linked incentive (PLI) scheme for bulk drugs (APIs) has boosted local production of some key APIs here, industry insiders say it would take at least 5-7 more years before India can see tangible results on the ground.
Data from the Pharmaceutical Exports Promotion Council (Pharmexcil) shows India imported $3.18 billion worth of APIs and intermediates from China in 2022-23, up 1.74 per cent from previous year. In 2021-22, India had imported $3.12 billion worth of APIs and intermediates from China, which was up 19.5 per cent from 2020-21. Therefore, the rate of growth has slowed down, but the imports still continue at similar levels.
On the other hand, India’s imports of bulk drugs and intermediates from the world (overall) came down by 4.54 per cent to $4.5 billion. This is in contrast to the previous year when they had grown by almost 23 per cent to $4.7 billion.
Uday Bhaskar, director general of Pharmexcil, told Business Standard: “The effect of the PLI scheme-induced production capacity of bulk drugs would take another few years to show results on the ground.”
Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA), which represents India’s top drug makers, said: “India has taken an integrated approach towards reducing dependence for API and KSM imports from China, and increasing local production. The scheme has started showing results, but it would take 5-7 years to reduce overall dependence. The diversified supply chain is fundamental for health care security going forward.”
The domestic pharma industry, however, pointed out that the reduction in imports has started for specific products. Before the PLI scheme was introduced, there was only one plant making Para Amino Phenol (used to make paracetamol), said Viranchi Shah, president of the Indian Drug Manufacturers Association (IDMA) that represents the small and medium pharma companies.
“We were highly dependent on China for this very important drug, which was used widely during the Covid pandemic. Now, at least three-four plants are making para-amino-phenol,” he said.
China also changes the prices of key material and bulk drugs and other chemicals when it sees that local production in India has gone up, said industry insiders.
“So, once we have the local production base for key products, then Indian pharma players can slowly reduce the dependence on China,” Bhaskar said.
Another industry veteran pointed out that China had started early. “They gave incentives in the form of power, land, and other subsidies to their chemical industry about 30-40 years back. We have grown dependent on them for the last 30 years, and we launched our PLI scheme only in 2021. So, it will take time,” he said.
Some industry insiders said once the production base was ready in India, the Centre can think of tariff barriers to incentivise the formulation makers to buy from domestic players. As such, there is a 25-30 per cent price premium when bought locally. As of February, around 22 projects to make key APIs came up under the PLI scheme. These units have a total installed capacity in excess of 33,000 tonnes.
These companies are making some key bulk drugs like para-amino-phenol, Atorvastatin (to make cholesterol drug), common antibiotic APIs like Sulfadiazine, Levofloxacin, Norfloxacin and Ofloxacin, vitamin APIs, common hypertension drugs like valsartan, and antivirals like lopinavir (for HIV positive patients). Companies like Meghmani LLP and Sadhana Nitro Chem have set up installed capacities of 13,500 tonnes and 12,000 tonnes for paracetamol API para-amino-phenol. Hetero has set up capacities to make four APIs.
The pharmaceuticals department rolled out a PLI scheme for bulk drugs with an outlay of Rs 6,940 crore. The incentive rates being offered under the scheme are 20 per cent for the first year, 15 per cent for the fifth year, and 5 per cent for the sixth year. The idea is to reduce dependence on Chinese imports.
In February, the Ministry of Chemicals and Fertilisers had said in a statement that 51 projects had been selected for 34 notified bulk drugs. “Against a committed investment of Rs 4,138 cr over the scheme period of six years, Rs 2,019 crore have been reported so far and the remaining will be realised in the coming year,” it said.
While the total amount disbursed under the bulk drug PLI is not known, industry insiders peg it to be less than Rs 100 crore. Under the PLI for pharmaceutical formulations, a separate scheme, the government had disbursed Rs 166 crore as of February.

Related Posts

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio, Inc. (Annovis), a phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced that…

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

The enforcement wing of Karnataka’s Food Safety and Drugs Control Department has seized medical devices and consumables worth ₹13.79 lakh from two establishments in Bengaluru’s Cottonpet area for alleged violations…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio receives US patent covering new crystalline form of buntanetap

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels